X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5582) 5582
Publication (705) 705
Book Chapter (77) 77
Book Review (51) 51
Conference Proceeding (23) 23
Dissertation (10) 10
Data Set (1) 1
Newspaper Article (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2771) 2771
index medicus (2643) 2643
animals (1656) 1656
male (1440) 1440
p2y (1257) 1257
clopidogrel (1137) 1137
p2y receptor (1109) 1109
female (1075) 1075
ticlopidine - analogs & derivatives (838) 838
pharmacology & pharmacy (834) 834
atp (812) 812
purinergic p2y receptor antagonists - therapeutic use (782) 782
p2y receptors (743) 743
middle aged (732) 732
cardiac & cardiovascular systems (725) 725
platelet aggregation inhibitors - therapeutic use (683) 683
adenosine - analogs & derivatives (662) 662
aged (638) 638
ticagrelor (621) 621
rats (604) 604
percutaneous coronary intervention (582) 582
neurosciences (575) 575
prasugrel (549) 549
hematology (542) 542
treatment outcome (538) 538
cell biology (527) 527
mice (512) 512
acute coronary syndromes (506) 506
purinergic p2y receptor antagonists - pharmacology (502) 502
receptors, purinergic p2 - metabolism (489) 489
biochemistry & molecular biology (484) 484
purinergic p2y receptor antagonists - administration & dosage (484) 484
blood platelets - drug effects (481) 481
activation (464) 464
peripheral vascular disease (464) 464
aspirin (453) 453
purinergic p2y receptor antagonists - adverse effects (442) 442
platelet aggregation - drug effects (439) 439
receptor (437) 437
ticlopidine - therapeutic use (433) 433
adenosine triphosphate - pharmacology (411) 411
platelet aggregation inhibitors - pharmacology (400) 400
platelet aggregation inhibitors - adverse effects (396) 396
platelet aggregation inhibitors - administration & dosage (388) 388
dose-response relationship, drug (387) 387
acute coronary syndrome - drug therapy (378) 378
extracellular atp (371) 371
blood platelets - metabolism (358) 358
calcium - metabolism (358) 358
adenosine (350) 350
cells, cultured (349) 349
prasugrel hydrochloride (346) 346
antiplatelet therapy (345) 345
time factors (345) 345
receptors (343) 343
abridged index medicus (339) 339
platelets (337) 337
thrombosis (334) 334
signal transduction (332) 332
adenosine - therapeutic use (331) 331
adenosine triphosphate - metabolism (331) 331
inhibition (330) 330
adp (327) 327
acute coronary syndrome (323) 323
physiology (308) 308
nucleotides (305) 305
adenosine diphosphate - pharmacology (302) 302
aggregation (298) 298
expression (297) 297
risk factors (295) 295
adult (285) 285
purinergic receptors (271) 271
cells (266) 266
ticlopidine - administration & dosage (258) 258
cardiovascular (257) 257
analysis (253) 253
myocardial-infarction (251) 251
receptors, purinergic p2 - genetics (246) 246
blood platelets (245) 245
platelet function tests (244) 244
inflammation (242) 242
purinergic p2 receptor antagonists (242) 242
calcium (240) 240
hemorrhage - chemically induced (239) 239
prospective studies (235) 235
aspirin - therapeutic use (230) 230
drug therapy, combination (228) 228
article (227) 227
platelet aggregation (226) 226
coronary heart disease (225) 225
receptors, purinergic p2 - physiology (224) 224
ticlopidine - adverse effects (224) 224
ticlopidine - pharmacology (220) 220
adenosine - administration & dosage (213) 213
cardiac patients (212) 212
rats, sprague-dawley (209) 209
receptors, purinergic p2y1 (208) 208
care and treatment (202) 202
p2x receptors (201) 201
platelet inhibition (201) 201
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5519) 5519
German (26) 26
Russian (21) 21
French (20) 20
Japanese (14) 14
Chinese (10) 10
Spanish (10) 10
Polish (9) 9
Italian (7) 7
Czech (3) 3
Danish (3) 3
Hungarian (2) 2
Turkish (2) 2
Ukrainian (2) 2
Catalan (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neuropharmacology, ISSN 0028-3908, 05/2016, Volume 104, pp. 31 - 49
Pharmacological tool compounds are now available to define action at the adenosine (ARs), P2Y and P2X receptors. We present a selection of the most commonly... 
Nucleosides | GPCR | Agonists | Antagonists | Nucleotides | Ion channel | ATP | PROTEIN-COUPLED RECEPTORS | ALLOSTERIC MODULATION | NEUROSCIENCES | NEUROPATHIC PAIN | NUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE | IN-VIVO | ION-CHANNEL | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | PURINERGIC RECEPTOR | P2Y RECEPTOR | STRUCTURE-BASED DESIGN | Purinergic P1 Receptor Agonists - chemistry | Receptors, Purinergic P2Y - chemistry | Receptors, Purinergic P2X - chemistry | Humans | Purinergic P1 Receptor Agonists - pharmacology | Receptors, Purinergic P2Y - metabolism | Purinergic P1 Receptor Antagonists - therapeutic use | Purinergic P2Y Receptor Agonists - chemistry | Purinergic P2Y Receptor Agonists - therapeutic use | Structure-Activity Relationship | Purinergic P1 Receptor Agonists - therapeutic use | Chemistry, Pharmaceutical | Purinergic P1 Receptor Antagonists - pharmacology | Purinergic P2Y Receptor Agonists - pharmacology | Receptors, Purinergic P1 - chemistry | Animals | Purinergic Agents - chemistry | Purinergic Agents - therapeutic use | Receptors, Purinergic P2X - metabolism | Receptors, Purinergic P1 - metabolism | Purinergic Agents - pharmacology | Purinergic P1 Receptor Antagonists - chemistry | Prevention | Brain | Purines | Enzymes | Injuries | Chronic pain | Cancer | antagonists | nucleosides | agonists | ion channel | nucleotides
Journal Article
Purinergic Signalling, ISSN 1573-9538, 9/2015, Volume 11, Issue 3, pp. 389 - 407
Adenosine receptors (ARs) have emerged as new drug targets. The majority of data on affinity/potency and selectivity of AR ligands described in the literature... 
Neurosciences | Agonist | Biomedicine | Human Physiology | Cancer Research | Selectivity | Potency | Antagonist | Pharmacology/Toxicology | Species differences | Biomedicine general | XANTHINE DERIVATIVES | NEUROSCIENCES | STRIATAL MEMBRANES | PROTEIN-COUPLED ADENOSINE | P2Y RECEPTORS | A(2B) RECEPTORS | INTERNATIONAL UNION | LIGANDS | A(2A) RECEPTOR | HIGHLY POTENT | PARKINSONS-DISEASE | Cricetulus | Species Specificity | Humans | DNA, Complementary - genetics | Adenosine A1 Receptor Antagonists - pharmacology | Adenosine A2 Receptor Agonists - metabolism | Receptor, Adenosine A2B - genetics | Structure-Activity Relationship | Adenosine A1 Receptor Antagonists - metabolism | Adenosine A2 Receptor Antagonists - metabolism | Adenosine A2 Receptor Agonists - pharmacology | Adenosine A3 Receptor Agonists - pharmacology | Adenosine A1 Receptor Agonists - pharmacology | Receptor, Adenosine A2B - drug effects | Receptor, Adenosine A2A - genetics | Adenosine A3 Receptor Antagonists - pharmacology | Cell Membrane - metabolism | Adenosine A3 Receptor Agonists - metabolism | Cyclic AMP - metabolism | Arrestin - metabolism | Cell Membrane - drug effects | DNA, Complementary - drug effects | CHO Cells | Cricetinae | Receptors, Purinergic P1 - genetics | Rats | Receptor, Adenosine A2A - metabolism | Receptor, Adenosine A2B - metabolism | Receptor, Adenosine A2A - drug effects | Binding, Competitive - drug effects | Adenosine A2 Receptor Antagonists - pharmacology | Animals | Adenosine A1 Receptor Agonists - metabolism | Adenosine A3 Receptor Antagonists - metabolism | Mice | Receptors, Purinergic P1 - metabolism | Receptors, Purinergic P1 - drug effects | Adenosine | Original
Journal Article
Purinergic Signalling, ISSN 1573-9538, 9/2012, Volume 8, Issue 3, pp. 419 - 436
The medicinal chemistry and pharmacology of the four subtypes of adenosine receptors (ARs) and the eight subtypes of P2Y receptors (P2YRs, activated by a range... 
Clinical trials, nucleosides | Neurosciences | Adenosine receptors | Human Physiology | P2Y receptors | Antagonists | Nucleotides | Biomedicine general | Biomedicine | GPCR structure | Cancer Research | Agonists | Pharmacology/Toxicology | PHYLOGENETIC ANALYSIS | A(2B) ADENOSINE | ANTAGONIST RECOGNITION | SITE-DIRECTED MUTAGENESIS | MUTATIONAL ANALYSIS | NEUROSCIENCES | NUCLEOTIDE RECEPTORS | INTERNATIONAL UNION | SUBTYPE SELECTIVITY | MOLECULAR RECOGNITION | PURINERGIC RECEPTORS | Receptors, G-Protein-Coupled - metabolism | Humans | Purinergic P2Y Receptor Agonists - therapeutic use | Purinergic P1 Receptor Agonists - therapeutic use | Purinergic P1 Receptor Antagonists - pharmacology | Receptors, Purinergic P1 - chemistry | Receptors, Purinergic P2 - chemistry | Drug Design | Receptors, G-Protein-Coupled - drug effects | Purinergic P2Y Receptor Antagonists - therapeutic use | Purinergic P2Y Receptor Antagonists - pharmacology | Purinergic P1 Receptor Agonists - chemistry | Purinergic P1 Receptor Agonists - pharmacology | Purinergic P1 Receptor Antagonists - therapeutic use | Purinergic P2Y Receptor Agonists - chemistry | Clinical Trials as Topic | Receptors, Purinergic P2 - drug effects | Purinergic P2Y Receptor Agonists - pharmacology | Animals | Purinergic P2Y Receptor Antagonists - chemistry | Receptors, Purinergic P2 - metabolism | Ligands | Receptors, Purinergic P1 - metabolism | Receptors, Purinergic P1 - drug effects | Receptors, G-Protein-Coupled - chemistry | Purinergic P1 Receptor Antagonists - chemistry | Glaucoma | Heart | Adenosine | Parkinson's disease | Psoriasis | Cystic fibrosis | Rheumatoid factor | Hepatitis | Alkaloids | Pyrimidines | Heterocyclic compounds | Emissions (Pollution) | Rheumatoid arthritis | Respiratory tract diseases | Eye diseases | G proteins | Diabetes | Ophthalmology | Kidney diseases | Hepatitis C | DNA-ligand interactions | Arrhythmia | Clinical trials | Ionizing radiation | Reperfusion | Ischemia | pyrimidines | Injuries | Movement disorders | Neurodegenerative diseases | Diabetes mellitus | Lung diseases | Pharmacology | Thrombosis | imaging | Stress | Purine P2Y receptors | purines | Hypoxia | Receptor mechanisms | ATP | Cancer | Pharmaceuticals | Original
Journal Article
Journal of Chemical Information and Modeling, ISSN 1549-9596, 05/2015, Volume 55, Issue 5, pp. 1045 - 61
Journal Article